HNRNPL and prostate carcinoma: In prostate cancer, heterogeneous nuclear ribonucleoprotein L (HnRNPL) inhibition reduced PD‐L1 expression, increased IFN‐γ production, and induced ferroptosis in CRPC cells through the STAT1/SLC7A11/GPX4 signalling pathways axis.